---
document_datetime: 2023-09-21 19:16:17
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/topotecan-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: topotecan-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.0222095
conversion_datetime: 2025-12-14 13:33:56.863185
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Topotecan Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0014              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 22/06/2018                          |                                             | SmPC, Labelling and PL           |           |
| IA/0013              | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                | 14/12/2017                          |                                             | Annex II and PL                  |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0012/G          | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data   | 15/07/2016   | n/a        |                            |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------|-----------------------------------|
| PSUSA/2997/ 201505 | Periodic Safety Update EU Single assessment - topotecan                                                                                                                                                                                                                                                                                                                                                                                           | 14/01/2016   | n/a        |                            | PRAC Recommendation - maintenance |
| IB/0010            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                      | 29/01/2015   | 11/03/2016 | SmPC, Annex II and PL      |                                   |
| IB/0009            | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                        | 12/12/2014   | n/a        |                            |                                   |
| T/0008             | Transfer of Marketing Authorisation fom Teva Pharma B.V. (Utrecht) and Teva B.V (Haarlem). Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                    | 12/11/2014   | 28/11/2014 | Annex II, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

| R/0007    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                       | 25/04/2014   | 19/06/2014   | SmPC, Labelling and PL   | Based on the CHMP review of data on quality, safety and efficacy, including all variations introduced since the marketing authorisation was granted, the CHMP considers by consensus that the risk-benefit balance of Topotecan Teva in the treatment of metastatic carcinoma of the ovary, relapsed small cell lung cancer [SCLC] and carcinoma of the cervix remains favourable and therefore recommends the renewal of the marketing authorisation with unlimited validity.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0006    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                              | 13/09/2013   | 19/06/2014   | PL                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| N/0005    | Update the contact details for the MAHrepresentatives in the Package Leaflet and for the Latvian translation, to bring the INN in line with the information on the Labeling. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 13/02/2013   | 19/06/2014   | PL                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IAIN/0004 | B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing                                                                                                                                               | 05/06/2012   | 25/10/2012   | Annex II and PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IB/0003   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data are submitted by the MAH                                | 11/02/2011   | n/a          | SmPC, Annex II and PL    | The MAH applied to bring the SmPC in line to reflect the changes made to the parent product Hycamtin. Few minor formatting changes have been added.                                                                                                                                                                                                                                                                                                                              |
| IB/0002   | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other                                                                                                                                                                 | 07/07/2010   | n/a          | SmPC                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|        | variation                                                                                        |            |     |                  |
|--------|--------------------------------------------------------------------------------------------------|------------|-----|------------------|
| N/0001 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 09/12/2009 | n/a | Labelling and PL |